Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Entry and Attachment Inhibitors

Ibalizumab-uiyk (Trogarzo, IBA)

Last Updated: December 24, 2019; Last Reviewed: December 24, 2019

Excerpt from Table 8

Excerpt from Table 8
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendationsa Use in Pregnancy
Ibalizumab
(IBA)
Trogarzo
IBA (Trogarzo):
  • Solution for IV infusion is available in single-dose vials
Standard Adult Dose:
  • IBA 2,000-mg loading dose, followed by IBA 800-mg maintenance doses administered every 2 weeks
Pregnancy
PKs in Pregnancy:
  • No PK studies in human pregnancy.
Dosing in Pregnancy:
  • Insufficient data to make dosing recommendations.
No data available, but placental transfer of IBA, a monoclonal antibody, is possible.

Insufficient data to assess for teratogenicity in humans.
a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 10).

Key: ARV = antiretroviral; IBA = ibalizumab; IV = intravenous; PK = pharmacokinetic

Download Guidelines